Skip to main content
Premium Trial:

Request an Annual Quote

Myriad Receives Patent On Method to Link Gene Markers with Disease

Premium

SALT LAKE CITY--Myriad Genetics here has been issued a US patent on a new method for rapidly determining whether known genetic markers are linked to particular diseases, which the company says is an important step in its gene discovery process. "The method is used to trace the genetic markers through families which have the disease," the company explained in a press release. "The technique is very powerful in defining a narrow chromosomal region which contains a disease-related gene, in a shorter period of time and with fewer individuals required than previous methods," according to Myriad.

Myriad is a genomics and genetic testing company that has strategic alliances with the major pharmaceutical companies Schering-Plough, Novartis, Bayer, and Eli Lilly. It uses two gene discovery approaches: positional cloning and ProNet, its proprietary database of proteins, their interacting partners, and their biochemical pathways, the company said.

Filed under

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.